Open Orphan plc (ORPH), the rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, is pleased to announce the latest copy of its investor presentation is now available to view on https://www.openorphan.com/investors/reasons-invest.
Open Orphan was also covered this weekend in the Sunday Times due to our unique reputation as being the world leader in this space having provided services for over 30 years to the vaccine production companies around the world.
